Vanda Pharmaceuticals Inc. (VNDA) Set to Announce Earnings on Tuesday
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will be releasing its earnings data after the market closes on Tuesday, October 31st. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.15) per share for the quarter.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. The company had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.01 earnings per share. On average, analysts expect Vanda Pharmaceuticals to post $-0.42 EPS for the current fiscal year and $-0.1 EPS for the next fiscal year.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 15.70 on Tuesday. The stock’s market capitalization is $704.27 million. Vanda Pharmaceuticals Inc. has a 12 month low of $12.70 and a 12 month high of $18.99. The stock has a 50 day moving average price of $17.33 and a 200 day moving average price of $15.76.
A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, August 29th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research note on Thursday, September 14th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. Finally, HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $21.29.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.